Download PDF
Synfacts 2011(12): 1273-1273  
DOI: 10.1055/s-0031-1289320
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag Stuttgart ˙ New York

Synthesis of BIRT2584

Contributor(s): Philip Kocienski
X.-J. Wang*, R. P. Frutos et al.*
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA; Boehringer Ingelheim Gmbh & Co KG, Ingelheim, Germany
Further Information

Publication History

Publication Date:
18 November 2011 (online)

    Permissions and Reprints

Significance

BIRT2584 inhibits lymphocyte function-associated antigen-1 (LFA-1). It is under development for the treatment of immune ailments, such as psoriasis and rheumatoid arthritis. The synthesis depicted was accomplished on a metric ton scale and features the use of ­Seebach’s self-regeneration of stereocenters protocol to install the single stereogenic center in E.